Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IGSF11 | Q5DX21 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282912 | 0.94 | L3MBTL1 (0.65) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283026 | 0.93 | L3MBTL1 (0.54) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283029 | 0.93 | RAB9A (0.60) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283021 | 0.87 | MAPT (0.63) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283027 | 0.87 | NPSR1 (0.53) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283030 | 0.87 | L3MBTL1 (0.63) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283031 | 0.85 | RAB9A (0.55) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13283035 | 0.85 | RAB9A (0.59) | L3MBTL1RAB9ALMNAUSP2NPSR1 | |
| SCHEMBL13282918 | 0.82 | NPSR1 (0.56) | L3MBTL1RAB9ALMNANPSR1SMN1; SMN2 | |
| SCHEMBL13283020 | 0.82 | ALDH1A1 (0.66) | L3MBTL1RAB9ALMNANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190746-A1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190746-A1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNK17, KCNQ2 | L3MBTL1 3260/4885RAB9A 560/4885LMNA 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.